CY1123093T1 - Φαρμακοφορο για την επαγωγη του trail - Google Patents
Φαρμακοφορο για την επαγωγη του trailInfo
- Publication number
- CY1123093T1 CY1123093T1 CY20201100267T CY201100267T CY1123093T1 CY 1123093 T1 CY1123093 T1 CY 1123093T1 CY 20201100267 T CY20201100267 T CY 20201100267T CY 201100267 T CY201100267 T CY 201100267T CY 1123093 T1 CY1123093 T1 CY 1123093T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trail
- imidazolinopyrimidinone
- trail gene
- compound
- inducing pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Γνωστοποιούνται ενώσεις ιμιδαζολινοπυριμιδινόνης οι οποίες έχουν δράση για να επάγουν την έκφραση των γονιδίων TRAIL σε μακροφάγα. Γνωστοποιείται περαιτέρω μια μέθοδος για την αγωγή διαφόρων καρκίνων η οποία περιλαμβάνει τη χορήγηση δραστικών ποσοτήτων μιας ιμιδαζολινοπυριμιδινόνης που έχει τη δομή του τύπου Ι στο παρόν. Η εφεύρεση προσανατολίζεται, σε διάφορες υλοποιήσεις, σε μια ένωση και μια φαρμακευτική σύνθεση που περιλαμβάνουν μια δραστική ποσότητα μιας ένωσης η οποία έχει τη δυνατότητα να επάγει την έκφραση του γονιδίου TRAILσε κύτταρα τα οποία έχουν τη δυνατότητα να εκφράζουν το γονίδιο TRAIL για να παραχθεί το TRAIL κυτοκίνης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461972689P | 2014-03-31 | 2014-03-31 | |
PCT/US2015/023362 WO2015153468A1 (en) | 2014-03-31 | 2015-03-30 | Pharmacophore for trail induction |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123093T1 true CY1123093T1 (el) | 2021-10-29 |
Family
ID=54241169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100267T CY1123093T1 (el) | 2014-03-31 | 2020-03-20 | Φαρμακοφορο για την επαγωγη του trail |
Country Status (18)
Country | Link |
---|---|
US (4) | US10239877B2 (el) |
EP (2) | EP3662910A1 (el) |
JP (4) | JP6756435B2 (el) |
KR (2) | KR102473930B1 (el) |
CN (2) | CN111499636B (el) |
AU (3) | AU2015241069B2 (el) |
CA (2) | CA2944452C (el) |
CY (1) | CY1123093T1 (el) |
DK (1) | DK3125898T3 (el) |
ES (1) | ES2779979T3 (el) |
HR (1) | HRP20200478T1 (el) |
HU (1) | HUE049013T2 (el) |
LT (1) | LT3125898T (el) |
PL (1) | PL3125898T3 (el) |
PT (1) | PT3125898T (el) |
RS (1) | RS60163B1 (el) |
SI (1) | SI3125898T1 (el) |
WO (1) | WO2015153468A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
HUE044238T2 (hu) | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra |
DK3546461T3 (da) * | 2013-11-15 | 2021-09-13 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy |
RS60163B1 (sr) | 2014-03-31 | 2020-05-29 | Scripps Research Inst | Farmakofor koji indukuje trail |
MX2017009841A (es) * | 2015-01-30 | 2018-02-09 | Oncoceutics Inc | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia. |
CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
NZ745425A (en) | 2016-01-29 | 2023-03-31 | Oncoceutics Inc | G protein-coupled receptor (gpcr) modulation by imipridones |
WO2018031987A1 (en) | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
GB2596010B (en) * | 2019-02-11 | 2023-03-01 | Madera Therapeutics Llc | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents |
MX2023001576A (es) | 2020-08-06 | 2023-05-09 | Eoetvoes Lorand Tudomanyegyetem | Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena. |
CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE786028A (fr) * | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
JPS5374893A (en) | 1976-12-15 | 1978-07-03 | Fujitsu Ltd | Driving method for semiconductor photosensitive device |
JPS6132833U (ja) | 1984-07-31 | 1986-02-27 | 日信工業株式会社 | デイスクブレ−キ装置 |
EP2303264B1 (en) | 2008-06-09 | 2018-04-04 | Allergan, Inc. | Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives |
JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス,インコーポレイテッド | K−ras変異を有する癌の治療 |
WO2012078448A1 (en) * | 2010-12-06 | 2012-06-14 | Schering Corporation | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
CN103391945B (zh) * | 2011-03-15 | 2016-11-09 | 奇斯药制品公司 | 异噁唑烷衍生物 |
EP2694678A2 (en) * | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
WO2012149546A2 (en) | 2011-04-29 | 2012-11-01 | The Penn State Research Foundation | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy |
WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
HUE044238T2 (hu) * | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra |
US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
US9181237B2 (en) * | 2013-10-04 | 2015-11-10 | Mallinckrodt Llc | Substituted berbines and their synthesis |
RS60163B1 (sr) | 2014-03-31 | 2020-05-29 | Scripps Research Inst | Farmakofor koji indukuje trail |
-
2015
- 2015-03-30 RS RS20200336A patent/RS60163B1/sr unknown
- 2015-03-30 EP EP19218049.5A patent/EP3662910A1/en active Pending
- 2015-03-30 CN CN202010184181.3A patent/CN111499636B/zh active Active
- 2015-03-30 SI SI201531141T patent/SI3125898T1/sl unknown
- 2015-03-30 CN CN201580021658.3A patent/CN106456643B/zh active Active
- 2015-03-30 CA CA2944452A patent/CA2944452C/en active Active
- 2015-03-30 EP EP15772254.7A patent/EP3125898B1/en active Active
- 2015-03-30 LT LTEP15772254.7T patent/LT3125898T/lt unknown
- 2015-03-30 CA CA3158795A patent/CA3158795A1/en active Pending
- 2015-03-30 WO PCT/US2015/023362 patent/WO2015153468A1/en active Application Filing
- 2015-03-30 PL PL15772254T patent/PL3125898T3/pl unknown
- 2015-03-30 AU AU2015241069A patent/AU2015241069B2/en active Active
- 2015-03-30 US US15/126,192 patent/US10239877B2/en active Active
- 2015-03-30 KR KR1020167029994A patent/KR102473930B1/ko active IP Right Grant
- 2015-03-30 HU HUE15772254A patent/HUE049013T2/hu unknown
- 2015-03-30 JP JP2016559887A patent/JP6756435B2/ja active Active
- 2015-03-30 KR KR1020227042050A patent/KR102611067B1/ko active IP Right Grant
- 2015-03-30 ES ES15772254T patent/ES2779979T3/es active Active
- 2015-03-30 PT PT157722547T patent/PT3125898T/pt unknown
- 2015-03-30 DK DK15772254.7T patent/DK3125898T3/da active
-
2019
- 2019-03-20 US US16/359,633 patent/US10633385B2/en active Active
- 2019-09-10 JP JP2019164086A patent/JP6873201B2/ja active Active
-
2020
- 2020-03-20 CY CY20201100267T patent/CY1123093T1/el unknown
- 2020-03-23 HR HRP20200478TT patent/HRP20200478T1/hr unknown
- 2020-04-14 US US16/848,032 patent/US20200283440A1/en not_active Abandoned
- 2020-12-11 AU AU2020286314A patent/AU2020286314A1/en not_active Abandoned
-
2021
- 2021-04-20 JP JP2021071035A patent/JP7186256B2/ja active Active
- 2021-07-12 US US17/372,894 patent/US11891392B2/en active Active
-
2022
- 2022-11-28 JP JP2022188821A patent/JP2023022184A/ja active Pending
- 2022-12-08 AU AU2022283729A patent/AU2022283729A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123093T1 (el) | Φαρμακοφορο για την επαγωγη του trail | |
CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1119707T1 (el) | Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης | |
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
CY1121706T1 (el) | Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
EA201891317A2 (ru) | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения | |
CY1124076T1 (el) | Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος | |
CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
CY1122364T1 (el) | Αναστολεις της ezh2 | |
EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |